Devices, systems, and methods for performing focused ultrasound-mediated blood-brain barrier opening (FUS-BBBO) are disclosed. Focused ultrasound (FUS) devices are disclosed that include an adapter configured to attach to an actuated mounting shaft of a stereotaxic system, a transducer housing configured to mount to the adapter, and a FUS transducer housed within the transducer housing. A FUS system is disclosed that includes the disclosed FUS device operatively coupled to a transducer driving system. A stereotaxic-guided FUS-BBB system is disclosed that includes the disclosed FUS system mounted to an actuated mounting shaft of a stereotaxic system.

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

An ultrasound emitting device, configured to selectively and reversibly break the blood-brain barrier of a patient, including a structure configured to be placed on at least one portion of the head of the patient, at least two ultrasound transducers coupled to the structure and configured to emit ultrasounds of diagnostic intensity. Also, a method for improving the bioavailability in brain tissue of at least one inflammation mediator in a patient. Further, a method for treating diseases of the central nervous system using the method for improving the bioavailability of inflammation mediators in a patient in need thereof, and method for treating diseases of the central nervous system using the device. Finally, the use of the device for the treatment of diseases of the central nervous system.

A kit comprising: a urinary catheter comprising a first and a second longitudinal lumens; an ultrasonic transducer disposed about said catheter; a balloon mounted on said catheter, and enclosing said transducer; and a reservoir containing an acoustic coupling medium, wherein: said catheter further comprises a first opening in said first longitudinal lumen, said first opening disposed inside said balloon and configured to inflate said balloon with at least some of said acoustic coupling medium, said catheter further comprises a second opening in said second longitudinal lumen, said second opening disposed outside said balloon and configured to deliver a therapeutic fluid into the urinary bladder, around said balloon, and activation of said transducer in said urinary bladder causes cavitation bubbles to form in said therapeutic fluid adjacent an internal surface of the urinary bladder, and little or no cavitation bubbles are formed in said acoustic coupling medium in said balloon.

The systems and methods disclosed herein relate generally to microbubble-assisted delivery of a therapeutic agent, such as a chemotherapeutic agent, to cells or tissue of interest, either in vitro or in vivo, that can be activated by directed ultrasound irradiation. For example, hydrophobic sonosensitizers can be incorporated in microbubble complexes to provide improved sonodynamic therapies.

A system for for treatment of wounds consists of a treatment housing, a fluid delivery mechanism for supplying debridement fluids to the wound treatment area, an evacuation mechanism for evacuation of debris from the treatment chamber. A handheld device is connected to the treatment housing, wherein its interior accommodates a laser source, a scanning device, an image recording device and at least one sensors/detectors, a control unit having a microprocessor for controlling operation of the system. The sensors detect concentration of various substances in the wound, and microprocessor analyzes data obtained by the sensors and generates signals to adjust parameters of the laser, the liquid dispensing nozzles and the suction outlet to optimize removal of necrotic tissue so as to ultimately to promote wound healing.

Compositions for topical treatment to reduce the appearance of the hyperpigmented lesions of melasma are presented. Such compositions include defensins in concentrations that are below those that exhibit antimicrobial activity, and can be in the form of a topically applied gel, lotion, wash, shampoo, cream, or mask. Various formulations for such compositions, which can include various pharmaceutically acceptable stabilizers, emollients, and fragrances, are provided.

Various approaches to focusing an ultrasound transducer includes causing the ultrasound transducer to transmit ultrasound waves to the target region; causing the detection system to indirectly measure the focusing properties; and based at least in part on the indirectly measured focusing properties, adjusting a parameter value associated with at least one of the transducer elements so as to achieve a target treatment power at the target region.

The present invention provides for devices and methods that improve in vivo delivery of a drug to a target tissue by transmitting ultrasonic energy to a liquid comprising a drug at the site of the target tissue. The ultrasonic energy improves delivery of the drug to the target tissue.

Systems and methods are disclosed for providing focused ultrasound treatment. A patient is screened to determine if focused ultrasound treatment is appropriate for the patient to treat a disorder. The patient is monitored to measure a plurality of wellness-related parameters for the patient and detect or predict an onset of symptoms associated with the disorder from the wellness-related parameters if focused ultrasound treatment has been determined to be appropriate. A personalized location for focused ultrasound treatment is determined for the patient according to at least one of the wellness-related parameters. At least one parameter associated with the focused ultrasound treatment is selected according to at least one of the wellness-related parameters. Focused ultrasound treatment is provided to the patient at the selected location using the selected at least one parameter. The p wellness-related parameters are measured after focused ultrasound treatment is provided to determine an effectiveness of the treatment.